[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019008782A - Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora. - Google Patents

Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.

Info

Publication number
MX2019008782A
MX2019008782A MX2019008782A MX2019008782A MX2019008782A MX 2019008782 A MX2019008782 A MX 2019008782A MX 2019008782 A MX2019008782 A MX 2019008782A MX 2019008782 A MX2019008782 A MX 2019008782A MX 2019008782 A MX2019008782 A MX 2019008782A
Authority
MX
Mexico
Prior art keywords
microflora
maintenance
glucosamine
nitrogen
containing compound
Prior art date
Application number
MX2019008782A
Other languages
English (en)
Other versions
MX389431B (es
Inventor
W Koenig David
A Vongsa Rebecca
Li Jingru
A Peed Lindsay
N Hollmaier Paige
F Joyner Cheryce
Original Assignee
Kimberly Clark Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Co filed Critical Kimberly Clark Co
Publication of MX2019008782A publication Critical patent/MX2019008782A/es
Publication of MX389431B publication Critical patent/MX389431B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones, particularmente composiciones útiles para mantener y apoyar una microflora saludable en el tracto urogenital de una mujer que podría conducir a una inhibición de las infecciones vaginales, así como también a métodos para tratar y evitar infecciones vaginales. Las composiciones útiles en apoyar una microflora sana, descritas en la presente descripción, incluyen generalmente un primer agente terapéutico que incluye a metil-D glucósido y un segundo agente terapéutico que incluye un compuesto que contiene nitrógeno a una cantidad terapéutica. En algunas modalidades, el compuesto que contiene nitrógeno puede ser, por ejemplo, L-Cisteína, Citidina, D-Asparagina, Pirimidina, D-Alanina, D-Glucosamina HC1, y N-Acetil-D-Glucosamina.
MX2019008782A 2017-02-28 2017-02-28 Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora. MX389431B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/019833 WO2018160158A1 (en) 2017-02-28 2017-02-28 Synergistic composition for maintenance of healthy balance of microflora

Publications (2)

Publication Number Publication Date
MX2019008782A true MX2019008782A (es) 2019-10-02
MX389431B MX389431B (es) 2025-03-20

Family

ID=63370175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008782A MX389431B (es) 2017-02-28 2017-02-28 Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.

Country Status (9)

Country Link
US (2) US12029748B2 (es)
KR (1) KR102769558B1 (es)
CN (1) CN110234325A (es)
AU (1) AU2017401761B2 (es)
BR (1) BR112019015239A2 (es)
GB (1) GB2574534B (es)
MX (1) MX389431B (es)
RU (1) RU2748651C2 (es)
WO (1) WO2018160158A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD938918S1 (en) 2019-10-09 2021-12-21 Orei, Llc Electrical plug adapter
USD939447S1 (en) 2019-10-09 2021-12-28 Paul Zeng Universal Supplies, LLC Electrical plug adapter

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190782B (en) 1981-06-15 1986-11-28 Mehesz,Ernoe,Hu Process for producing pharmaceutical compositions for profilacting and treating negative changes of hygienics on epithelium
SE8603338D0 (sv) 1986-08-07 1986-08-07 Bjorn Andersch Medel for behandling av tillstand i slidan
US5171575A (en) 1987-01-19 1992-12-15 Nisshin Flour Milling Co., Ltd. Process for preventing diarrhea in animals
JPH0753174B2 (ja) 1987-06-12 1995-06-07 ライオン株式会社 消臭剤
IT1227154B (it) 1988-08-05 1991-03-19 A Tosi Farmaceutici S R L Nova Composizioni farmaceutiche per uso ginecologico a base di lattobacilli
US5389369A (en) 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
FR2678166B1 (fr) 1991-06-27 1993-10-22 Bioeurope Compositions cosmetiques contenant des glucooligosaccharides.
UA39965C2 (uk) 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )
RU2095073C1 (ru) 1994-02-25 1997-11-10 Российский научно-исследовательский противочумный институт "Микроб" Способ лечения воспалительных заболеваний урогенитального тракта, вызванных бактериальной микрофлорой
CZ297431B6 (cs) 1994-08-04 2006-12-13 Quadrant Holdings Cambridge Limited Prostredek obsahující dodávací systém pevné dávkypro prímou aplikaci v pevné forme a zpusob jeho výroby
SE9501056D0 (sv) 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
US5801116A (en) 1995-04-07 1998-09-01 Rhodia Inc. Process for producing polysaccharides and their use as absorbent materials
WO1997029763A1 (en) 1996-02-14 1997-08-21 The Procter & Gamble Company Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
CA2245810A1 (en) 1996-02-14 1997-08-21 The Procter & Gamble Company Urogenital and intestinal compositions
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO1998046206A1 (en) 1997-04-16 1998-10-22 Peregrine Pharmaceutical, Inc. Skin cream composition
US6716435B1 (en) 1997-04-18 2004-04-06 Ganeden Biotech, Inc. Absorbent product containing absorbent structure and Bacillus coagulans
US7507402B1 (en) 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US5958104A (en) * 1997-09-11 1999-09-28 Nonomura; Arthur M. Methods and compositions for enhancing plant growth
DE69831609T2 (de) 1997-11-24 2006-02-02 Zeng, Zhongming, Shenzhen Pharmazeutische zusammensetzung zur stimulierung des wachstums von gram-positiven bazillen und zur erhöhung der azidität der vagina und ihre verwendung
JP3665852B2 (ja) 1998-03-10 2005-06-29 日本甜菜製糖株式会社 抗アトピー性皮膚炎組成物
JP2000189109A (ja) 1999-01-04 2000-07-11 Terumo Corp 液状食品
ES2226228T5 (es) 1999-04-30 2009-01-16 Societe Des Produits Nestle S.A. Crecimiento mejorado de las bacterias del acido lactico en la leche.
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
AU2001281489A1 (en) 2000-03-10 2001-10-03 Trustees Of Tufts College NIMR compositions and their methods of use
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
SE521022C2 (sv) 2001-09-20 2003-09-23 Ellen Ab Mjölksyraproducerande bakterier för användning som probiotiska organismer i vaginan hos människa
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
WO2004007695A2 (en) 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
SI1485463T1 (sl) 2002-03-21 2009-02-28 Bifodan As Sevi Lactobacillusa
JP3885204B2 (ja) 2002-04-16 2007-02-21 株式会社Ｃａｃ 細胞活性促進外用剤
CA2488011C (en) 2002-06-03 2008-02-12 Cac Corporation External preparations for treating dermatitis
JP2004026725A (ja) 2002-06-26 2004-01-29 Sunstar Inc 固形製剤
EP1565547B2 (en) 2002-06-28 2012-09-19 Biosearch S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
WO2004064850A1 (en) 2003-01-23 2004-08-05 Ml Laboratories Plc Antiviral composition comprising a sulphated glucose polymer and a bacteriostatic agent
WO2004076615A2 (en) 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
EP1462011A1 (en) 2003-03-24 2004-09-29 Cerestar Holding B.V. Comestibles containing Isomaltulose and Trehalose for sustained carbohydrate energy release and reduced glycemic/insulinimic responses
US7182954B1 (en) 2003-04-04 2007-02-27 The United States Of America, As Represented By The Secretary Of Agriculture Prebiotic oligosaccharides via alternansucrase acceptor reactions
ITTO20030404A1 (it) 2003-05-30 2004-11-30 Rottapharm S R L Composizione per il ripristino dell'ecosistema vaginale
DE10325404B4 (de) 2003-06-05 2013-05-29 Willy Thenn Wässriges Suspensionsmedium mit lebensfähigen Milchsäurebakterien für probiotische Anwendungen
BRPI0411429A (pt) 2003-06-13 2006-07-25 Idh Holding Aps tratamento de sintomas associados com vaginose bacteriana
DE10328180A1 (de) 2003-06-16 2005-01-13 Südzucker AG Mannheim/Ochsenfurt Verwendung von Isomalt als Präbiotikum
JP4553604B2 (ja) 2003-06-30 2010-09-29 明治製菓株式会社 一般食品、保健機能食品または健康補助食品の機能増強組成物及びその方法
US6967949B2 (en) 2003-09-15 2005-11-22 Teknovus, Inc. Method and apparatus for forwarding packets in an ethernet passive optical network
WO2005060937A1 (en) 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
MXPA06012070A (es) 2004-04-20 2007-04-24 Univ Chicago Sistema de surtido terapeutico que comprende un compuesto de tipo peg de peso molecular alto.
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
EP1614357A1 (en) 2004-07-10 2006-01-11 Cognis IP Management GmbH Dietary supplements comprising prebiotics and fatty acid
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US7619008B2 (en) 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20090028839A1 (en) 2004-12-23 2009-01-29 Tchikindas Mikhail L Compositions and methods for the prophylaxis and treatment of vaginal infections
JP2006191830A (ja) 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
CN101175503B (zh) 2005-04-27 2012-12-12 深圳福诺生物技术有限公司 一种调节并保持阴道菌群和阴道酸度正常的组合物与方法
HUP0500582A1 (hu) 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok
US7786176B2 (en) 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
EP1946760A4 (en) 2005-10-13 2009-07-22 Meiji Seika Kaisha COMPOSITION FOR IMPROVING INTESTINAL FLORA
CA2626122A1 (en) 2005-11-15 2007-05-24 Baxter International, Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
US9144251B2 (en) 2005-11-23 2015-09-29 The Coca-Cola Company High-potency sweetener composition with mineral and compositions sweetened therewith
CA2624281A1 (en) 2005-12-20 2007-06-28 Sca Hygiene Products Ab New article
RU2382655C1 (ru) 2005-12-22 2010-02-27 Ска Хайджин Продактс Аб Адсорбирующее изделие
US20090163427A1 (en) 2006-04-10 2009-06-25 Aleksander Vladimirovich Dikovskiy Pharmaceutical Composition of Enterosorbent and Prebiotics, Dosage Forms, and the Method for Prevention and Treatment of Gastrointestinal Disorders
MY149152A (en) * 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
US9119779B2 (en) 2006-06-12 2015-09-01 The Procter & Gamble Company Lotioned wipe product comprising an anti-stick agent and a performance enhancing agent
US8221774B2 (en) 2006-06-12 2012-07-17 The Procter & Gamble Company Lotioned wipe product to reduce adhesion of soils or exudates to the skin
JP2010508886A (ja) 2006-11-02 2010-03-25 エスセーアー・ハイジーン・プロダクツ・アーベー 供給デバイス
US9101161B2 (en) 2006-11-02 2015-08-11 The Coca-Cola Company High-potency sweetener composition with phytoestrogen and compositions sweetened therewith
US8222020B2 (en) 2006-11-17 2012-07-17 Sca Hygiene Products Ab Biologically pure strain of Lactobacillus fermentum, strain Ess-1
EP1992367B1 (en) 2007-05-15 2012-06-27 The Procter & Gamble Company Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
US20120093753A1 (en) 2007-06-29 2012-04-19 Fevola Michael J Cationic polyglyceryl compositions and compounds
CN101411714A (zh) 2007-10-15 2009-04-22 杜军 治疗阴道炎的化学物质
US8642029B2 (en) 2008-03-31 2014-02-04 Osel, Inc. Transiently buffered Lactobacillus preparations and use thereof
ITMI20080949A1 (it) 2008-05-22 2009-11-23 Sinclair Pharma Srl Nuovo ceppo del genere lactobacillus e formulazioni farmaceutiche topiche che lo contengono
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
US20110105448A1 (en) 2008-06-06 2011-05-05 Glenmark Pharmaceuticals Limited Stable Topical Formulation Comprising Voriconazole
FR2933617B1 (fr) * 2008-07-10 2010-09-17 Alliospharma Compositions visant a favoriser le developpement et la croissance d'une microflore vaginale benefique
WO2010027349A1 (en) 2008-09-03 2010-03-11 Transdermal Innovations Inc. Multipurpose hydrogel compositions and products
EA024145B1 (ru) 2008-09-30 2016-08-31 Александр Владимирович ДИКОВСКИЙ Фармацевтическая композиция антимикотиков и пребиотиков и способ лечения кандидозных вагинитов
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010062707A1 (en) 2008-10-30 2010-06-03 Joule Unlimited, Inc. Methods and compositions for producing carbon-based products of interest in micro-organisms
EP2352528B1 (en) 2008-11-14 2019-08-14 The Procter and Gamble Company Substrate with adherence for feces and menses
AP3204A (en) 2008-11-30 2015-03-31 Univ Witwatersrand Jhb A controlled release intravaginal polymeric pharmaceutical dosage form
WO2010108314A1 (zh) 2009-03-24 2010-09-30 淮北中润生物能源技术开发有限公司 纤维戊糖或含有纤维戊糖的组合物在制备预防和/或治疗糖尿病患者机体酸化的食品或药物中的用途
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
FI122247B (fi) 2009-08-12 2011-10-31 Vetcare Oy Probioottinen valmiste koiran maha- ja suolistokanavassa ilmenevien häiriöiden ennaltaehkäisemiseksi tai hoitamiseksi
US8258250B2 (en) 2009-10-07 2012-09-04 Johnson & Johnson Consumer Companies, Inc. Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof
US8765819B2 (en) 2009-10-08 2014-07-01 Zhongming Zeng Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof
KR101133723B1 (ko) 2009-10-19 2012-04-09 최원석 소금 및 당을 유효성분으로 함유하는 질염 예방 및 치료용 조성물 및 이의 용도
US9408868B2 (en) 2009-10-19 2016-08-09 Won Seog Choi Skin external composition comprising a combination of sodium chloride and glucose as active ingredients for treating vaginosis and the use thereof
NL1037411C2 (nl) 2009-10-23 2011-04-27 Pk Peters Krizman Sa Samenstelling omvattende anijszuur, een derivaat daarvan en/of een farmaceutisch acceptabel zout hiervan en een zure buffer, evenals een doseringsvorm en toepassingen hiervan.
US20110118686A1 (en) 2009-11-13 2011-05-19 The Procter & Gamble Company Substrate with adherence for feces and menses
JP2011157348A (ja) 2010-01-05 2011-08-18 Fuji Chem Ind Co Ltd 崩壊性高強度球状粒子組成物
US8445226B2 (en) 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
RU2012154298A (ru) 2010-07-02 2014-08-10 Дзе Проктер Энд Гэмбл Компани Филаменты, содержащие пригодные для приема внутрь активные агенты, нетканые полотна и способы их изготовления
EP2588091B1 (en) 2010-07-02 2020-04-15 The Procter and Gamble Company Methods of delivering a health care active by administering personal health care articles comprising a filament
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
JP6088821B2 (ja) 2010-08-19 2017-03-01 株式会社明治 乳酸菌および／またはビフィズス菌の生残性向上剤
WO2012031186A1 (en) 2010-09-03 2012-03-08 Wisconsin Pharmacal Company, Llc. Prebiotic suppositories
CN103347395B (zh) 2010-12-06 2016-08-10 德嘉玛贝里尔有限公司 用于改进益生菌及其食物产品的稳定性并延长保质期的组合物和方法
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
WO2013010037A1 (en) 2011-07-12 2013-01-17 Lyrical Foods, Inc. Methods and compositions for consumables
JP2013018757A (ja) 2011-07-13 2013-01-31 Lion Corp 口腔用組成物
US20130022586A1 (en) 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
CN102370598A (zh) 2011-09-30 2012-03-14 天津市中科健新材料技术有限公司 一种用于湿巾的益生元香体整理液
JP5927663B2 (ja) 2011-10-21 2016-06-01 松谷化学工業株式会社 血糖値の上昇が緩やかな糖質組成物及び飲食品
RU2473347C1 (ru) 2011-11-09 2013-01-27 Сергей Константинович Панюшин Композиция пребиотиков для нормализации микрофлоры организма
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US9439863B2 (en) 2012-02-08 2016-09-13 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
CN102559561B (zh) 2012-02-24 2014-04-02 华东理工大学 一种食源性乳酸菌及其应用
RU2484669C1 (ru) 2012-04-06 2013-06-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ульяновский государственный университет" Способ коррекции дисбиоза влагалища при метаболическом синдроме
RU2486913C1 (ru) * 2012-06-25 2013-07-10 Антон Евгеньевич Супрун Средство для спринцевания влагалища в первую фазу лечения бактериального вагиноза
WO2014012805A1 (en) 2012-07-16 2014-01-23 Laccure Ab Pharmaceutical compositions containing oligomeric lactic acid
WO2014027006A1 (en) 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Bioadhesive formulations for use in drug delivery
WO2014026707A1 (en) 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Anti-vaginitis compositions with improved release and adherence
CN102870987B (zh) 2012-09-19 2013-12-11 广州立达尔生物科技股份有限公司 一种用于改善幼龄动物肠道发育的绿色饲料添加剂
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014106541A1 (en) 2013-01-04 2014-07-10 Ellen Ab Dermal composition for use in the external genital area in females
US20150320675A1 (en) 2013-01-18 2015-11-12 University Of Utah Research Foundation Modified Release Osmotic Pump for PH-Responsive Drug Delivery
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US11185562B2 (en) * 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
KR102159691B1 (ko) 2013-03-15 2020-09-24 아미리스 인코퍼레이티드 아세틸-코엔자임 a 유래 화합물을 생산하기 위한 포스포케톨라제 및 포스포트랜스아세틸라제의 용도
CN103255679B (zh) 2013-05-06 2015-11-25 金红叶纸业集团有限公司 抗菌混合液、抗菌纸及抗菌纸生产工艺
FI10563U1 (fi) 2014-03-07 2014-08-05 Selekta Henkilöstöpalvelut Oy Muotoiltava lista
WO2015135470A1 (zh) 2014-03-13 2015-09-17 曾忠铭 一种阴道用组合物与该组合物的用途
EP3270938A4 (en) 2015-03-18 2018-12-19 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
AU2015410635B2 (en) 2015-09-29 2021-08-19 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
KR20180054653A (ko) 2015-09-29 2018-05-24 킴벌리-클라크 월드와이드, 인크. 락토바실러스 우세를 유지하기 위한 조성물

Also Published As

Publication number Publication date
GB2574534B (en) 2022-06-08
RU2748651C2 (ru) 2021-05-28
US12029748B2 (en) 2024-07-09
GB2574534A (en) 2019-12-11
AU2017401761A8 (en) 2019-09-26
RU2019126148A3 (es) 2021-02-19
RU2019126148A (ru) 2021-02-19
KR102769558B1 (ko) 2025-02-19
BR112019015239A2 (pt) 2020-04-14
WO2018160158A1 (en) 2018-09-07
US20240307428A1 (en) 2024-09-19
AU2017401761B2 (en) 2023-08-31
CN110234325A (zh) 2019-09-13
MX389431B (es) 2025-03-20
KR20190120235A (ko) 2019-10-23
GB201912985D0 (en) 2019-10-23
AU2017401761A1 (en) 2019-09-05
US20200009174A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
BR112018010024A8 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2018002533A (es) Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
MX2019008782A (es) Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
BR112022018770A2 (pt) Composição alogênica compreendendo células t vd1+, dose, e, método de tratamento de uma malignidade mieloide